Low basal metabolic rate as a risk factor for development of insulin resistance and type 2 diabetes.
basal metabolism
diabetes mellitus, experimental
insulin resistance
obesity
Journal
BMJ open diabetes research & care
ISSN: 2052-4897
Titre abrégé: BMJ Open Diabetes Res Care
Pays: England
ID NLM: 101641391
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
19
03
2020
revised:
01
06
2020
accepted:
08
06
2020
entrez:
22
7
2020
pubmed:
22
7
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
Identification of physiological factors influencing susceptibility to insulin resistance and type 2 diabetes (T2D) remains an important challenge for biology and medicine. Numerous studies reported energy expenditures as one of those components directly linked to T2D, with noticeable increase of basal metabolic rate (BMR) associated with the progression of insulin resistance. Conversely, the putative link between genetic, rather than phenotypic, determination of BMR and predisposition to development of T2D remains little studied. In particular, low BMR may constitute a considerable risk factor predisposing to development of T2D. We analyzed the development of insulin resistance and T2D in 20-week-old male laboratory mice originating from three independent genetic line types. Two of those lines were subjected to divergent, non-replicated selection towards high or low body mass-corrected BMR. The third line type was non-selected and consisted of randomly bred animals serving as an outgroup (reference) to the selected line types. To induce insulin resistance, mice were fed for 8 weeks with a high fat diet; the T2D was induced by injection with a single dose of streptozotocin and further promotion with high fat diet. As markers for insulin resistance and T2D advancement, we followed the changes in body mass, fasting blood glucose, insulin level, lipid profile and We found BMR-associated differentiation in standard diabetic indexes between studied metabolic lines. In particular, mice with low BMR were characterized by faster body mass gain, blood glucose gain and deterioration in lipid profile. In contrast, high BMR mice were characterized by markedly higher expression of the Our study suggests that genetically determined low BMR makeup involves metabolism-specific pathways increasing the risk of development of insulin resistance and T2D.
Identifiants
pubmed: 32690630
pii: 8/1/e001381
doi: 10.1136/bmjdrc-2020-001381
pmc: PMC7373309
pii:
doi:
Substances chimiques
Blood Glucose
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Int J Obes (Lond). 2005 Mar;29(3):287-91
pubmed: 15672106
Eur J Clin Nutr. 2000 Aug;54(8):610-4
pubmed: 10951508
Mol Cell Biol. 2008 May;28(9):2971-9
pubmed: 18316403
J Comp Physiol B. 2020 Jan;190(1):101-112
pubmed: 31873784
PLoS One. 2019 Dec 5;14(12):e0220215
pubmed: 31805043
Transplantation. 2018 Feb;102(2S Suppl 1):S47-S49
pubmed: 28263222
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Obes Rev. 2015 Feb;16 Suppl 1:36-44
pubmed: 25614202
Diabetologia. 2013 May;56(5):1129-39
pubmed: 23423668
J Diabetes Res. 2016;2016:9051426
pubmed: 27595114
Diabetes. 2007 Nov;56(11):2655-67
pubmed: 17827399
Curr Diab Rep. 2014;14(11):551
pubmed: 25344220
Cell. 2012 Apr 13;149(2):274-93
pubmed: 22500797
Diabetes. 2004 Dec;53 Suppl 3:S215-9
pubmed: 15561913
Cell Metab. 2018 Feb 6;27(2):314-331
pubmed: 29275961
Diabetes Care. 2013 May;36(5):1095-101
pubmed: 23404301
Obesity (Silver Spring). 2010 Jan;18(1):71-8
pubmed: 19478787
J Leukoc Biol. 2019 Aug;106(2):385-395
pubmed: 29578634
Twin Res Hum Genet. 2015 Dec;18(6):762-71
pubmed: 26678054
Diabetologia. 2001 May;44(5):537-43
pubmed: 11380071
Evol Appl. 2015 Jan;8(1):2-8
pubmed: 25667599
Cell Death Dis. 2013 Dec 12;4:e964
pubmed: 24336084
Adv Pharmacol Sci. 2016;2016:9463476
pubmed: 26880906
BMC Genet. 2016 Jan 05;17:10
pubmed: 26728312
Mol Metab. 2014 Mar 21;3(4):460-4
pubmed: 24944905
Int J Mol Sci. 2018 Jul 13;19(7):
pubmed: 30011848
Clin Nutr. 2010 Feb;29(1):13-7
pubmed: 19788950
Front Endocrinol (Lausanne). 2019 Aug 07;10:548
pubmed: 31440209
Mol Metab. 2014 Jun 27;3(6):630-41
pubmed: 25161886
Cardiovasc Diabetol. 2013 Jan 16;12:17
pubmed: 23320821
Am J Clin Nutr. 2016 Oct;104(4):959-963
pubmed: 27581474
Front Nutr. 2016 Dec 22;3:56
pubmed: 28066773
Am J Clin Nutr. 2006 May;83(5):1076-81
pubmed: 16685049
Obesity (Silver Spring). 2019 May;27(5):691-699
pubmed: 31012296
Nutrients. 2018 Oct 14;10(10):
pubmed: 30322196
J Gerontol A Biol Sci Med Sci. 2015 Nov;70(11):1297-303
pubmed: 25409892
BMJ Open Diabetes Res Care. 2019 Mar 25;7(1):e000648
pubmed: 31114702
J Diabetes Res. 2018 Apr 30;2018:6106051
pubmed: 29854823
Curr Obes Rep. 2017 Dec;6(4):362-370
pubmed: 29101738
PLoS One. 2017 Feb 24;12(2):e0172892
pubmed: 28235091
J Biol Chem. 2017 Nov 24;292(47):19135-19145
pubmed: 28982973
Am J Physiol Endocrinol Metab. 2009 Aug;297(2):E271-88
pubmed: 19318514
FEBS J. 2012 Jun;279(11):1943-52
pubmed: 22429392
J Exp Biol. 2011 May 15;214(Pt 10):1714-20
pubmed: 21525318
J Comp Physiol B. 2013 Jan;183(1):27-41
pubmed: 22847501
Biomed Pharmacother. 2018 May;101:155-161
pubmed: 29486333
Br J Pharmacol. 2012 Jun;166(3):877-94
pubmed: 22352879
Curr Opin Genet Dev. 2018 Jun;50:86-95
pubmed: 29529423
Diabetes Res Clin Pract. 2015 Nov;110(2):101-8
pubmed: 26421362